Effects of PI3K inhibition and low docosahexaenoic acid on cognition and behavior

Physiology and Behavior

Volumn 100, Issue 3, 2010, Pages 239-244

  Bandaru, Sathyajit S ^a   Lin, Kristen ^a   Roming, Stephanie L ^a   Vellipuram, Ramana ^a   Harney, Jacob P ^a  

^a UNIVERSITY OF HARTFORD   (United States)

Author keywords

Alzheimer's disease; Diabetes; Docosahexaenoic acid; PI3 kinase; Wortmannin

Indexed keywords

DOCOSAHEXAENOIC ACID; GLUCOSE; INSULIN; PHOSPHATIDYLINOSITOL 3 KINASE; WORTMANNIN; ANDROSTANE DERIVATIVE; GLUCOSE BLOOD LEVEL; PHOSPHODIESTERASE INHIBITOR;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; COGNITION; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LEARNING; MALE; MAZE TEST; MEMORY; MOUSE; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; SPATIAL MEMORY; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; MOTOR ACTIVITY; PSYCHOLOGY;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROSTADIENES; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; BLOOD GLUCOSE; COGNITION; DEPRESSION; DOCOSAHEXAENOIC ACIDS; DRUG THERAPY, COMBINATION; INSULIN; MALE; MEMORY; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; PHOSPHODIESTERASE INHIBITORS; PHOSPHATIDYLINOSITOL 3-KINASES;

EID: 77952287179     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.physbeh.2009.10.019     Document Type: Article

References (53)

1. Rodger W. Non-insulin-dependent (Type II) diabetes mellitus. CMAJ 1991, 145:1571-1581.
2. Greenfield J., Campbell L. Insulin resistance and obesity. Clin Dermatol 2004, 22:289-295.
3. Götz J., Ittner L.M., Lim Y.A. Common features between diabetes mellitus and Alzheimer's disease. Cell Mol Life Sci 2009, 66:1321-1325.
4. Beck-Nielsen H., Groop L.C. Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. J Clin Invest 1994, 94:1714-1721.
5. Nicolls M.R. The clinical and biological relationship between type II diabetes mellitus and Alzheimer's disease. Curr Alzheimer Res 2004, 1:47-54.
6. Biessels G.J., Kappelle L.J. Utrecht Diabetic Encephalopathy Study Group. Increased risk of Alzheimer's disease in type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology?. Biochem Soc Trans 2005, 33:1041-1044.
7. Kahn C. Insulin action, diabetogenesis, and the cause of type II diabetes. Diabetes 1994, 43:1066-1084.
8. Ho L., Qin W., Pompl P.N., Xiang Z., Wang J., Zhao Z., et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 2004, 18:902-904.
9. Plum L., Schubert M., Bruning J.C. The role of insulin receptor signaling in the brain. Trends Endocrinol Metab 2005, 16:59-65.
10. Banks W.A., Kastin A.J. Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amylin. Peptides 1998, 19:883-889.
11. Cole G.M., Frautschy S.A. The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's disease. Exp Gerontol 2007, 42:10-21.
12. Sengupta A., Grundke-Iqbal I., Iqbal K. Regulation of phosphorylation of tau by protein kinases in rat brain. Neurochem Res 2006, 31:1473-1480.
13. Li Z.G., Zhang W., Sima A.A.F. Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 2007, 56:1817-1824.
14. Hooper C., Killick R., Lovestone S. The GSK3 hypothesis of Alzheimer's disease. J Neurochem 2008, 104:1433-1439.
15. Dimakopoulos A. Protein aggregation in Alzheimer's disease and other neuropathological disorders. Curr Alzheimer Res. 2005, 2:19-28.
16. Golde T.E., Dickson D., Hutton M. Filling the gaps in the Aβ cascade hypothesis of Alzheimer's disease. Curr Alzheimer's Res. 2006, 3:421-430.
17. Wang J.Z., Grundke-Iqbal I., Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci. 2007, 25:59-68.
18. Stoothoff W.H., Johnson G.V. Tau phosphorylation: physiological and pathological consequences. Biochim Biophys Acta 2005, 1739:280-297.
19. Authier F., Posner B.I., Bergeron J.J. Insulin-degrading enzyme. Clin Invest Med 1996, 19:149-160.
20. Calon F., Lim G.P., Morihara T., Yang F.S., Ubeda O., Salem N., et al. Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease. Eur J Neurosci 2005, 22:617-626.
21. Cohen G.M. Caspases: the executioners of apoptosis. Biochem J 1997, 326:1-16.
22. Zhao L., Teter B., Morihara T., Lim G.P., Ambegaokar S.S., Ubeda O.J., et al. Insulin degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J Neurosci 2004, 24:11,120-11,126.
23. Farris W., Mansourian S., Chang Y., Lindsley L., Eckman E.A., Frosch M.P., et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA 2003, 100:4162-4167.
24. Ackermann T.F., Hörtnagl H., Wolfer D.P., Colacicco G., Sohr R., Lang F., et al. Phosphatidylinositide dependent kinase deficiency increases anxiety and decreases GABA and serotonin abundance in the amygdala. Cell Physiol Biochem 2008, 22:735-744.
25. Ou L.C., Gean P.W. Regulation of amygdala-dependent learning by brain-derived neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol-3-kinase. Neuropscycopharmacology 2006, 31:287-296.
26. Calon F., Lim G.P., Yang F., Morihara T., Teter B., Ubeda O., et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004, 43:633-645.
27. Micheau J., Riedel G. Protein kinases: which one is the memory molecule?. CMLS 1999, 55:534-548.
28. Vanhaesebroeck B., Alessi D. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J 2000, 346:561-576.
29. Ferrer I., Gomez-Isla T., Puig B., Freixes M., Ribé E., Dalfó E., et al. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res 2005, 2:3-18.
30. Messier C., Teutenberg K. The role of insulin, insulin growth factor, and insulin-degrading enzyme in brain aging and Alzheimer's disease. Neural Plast 2005, 12:311-328.
31. Clodfelder-Miller B.J., Zmijewska A.A., Johnson G.V.W., Jope R.S. Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Diabetes 2006, 55:3320-3325.
32. Kurtuncu M., Luka L.J., Dimitrijevic N., Uz T., Manev H. Reliability assessment of an automated forced swim test device using two mouse strains. J Neurosci Methods 2005, 149:26-30.
33. Gersner R., Dar D.E., Shabat-Simon M., Zangen A. Behavioral analysis during the forced swimming test using a joystick device. J Neurosci Methods 2005, 143:117-121.
34. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984, 11:47-60.
35. Graziano A., Petrosini L., Bartoletti A. Automatic recognition of explorative strategies in the Morris water maze. J Neurosci Methods 2003, 130:33-44.
36. Podhorna J., Brown R.E. Strain differences in activity and emotionality do not account for differences in learning and memory performance between C57BL/6 and DBA/2 mice. Genes Brain Behav 2002, 1:96-110.
37. Savage L.M., Buzzetti R.A., Ramirez D.R. The effects of hippocampal lesions on learning, memory, and reward expectancies. Neurobiol Learn Mem 2004, 82:109-119.
38. Kendler K.S. Major depression and generalized anxiety disorder: same genes, (partly) different environments-revisited. Br J Psychiatry 1996, 168:68-75. Suppl.
39. 6 antagonists in the rat forced swimming test: potential therapeutic utility in mood disorders associated with Alzheimer's disease. Life Sci 2009, 84:558-562.
40. Ozaita A., Puighermanal E., Maldonado R. Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. J Neurochem 2007, 102:1105-1114.
41. Jope R.S., Johnson G.V. The glamour and gloom of glycogen synthase kinase-3. Trends Biochem Sci 2004, 29:95-102.
42. Peltier J., O'Neill A., Schaffer D.V. PI3K/Akt and CREB regulate adult neural hippocampal progenitor proliferation and differentiation. Dev Neurobiol 2007, 67:1348-1361.
43. Pandey S.C., Roy A., Zhang H. The decreased phosphorylation of cyclic adenosine monophosphate (cAMP) response element binding (CREB) protein in the central amygdala acts as a molecular substrate for anxiety related to ethanol withdrawal in rats. Alcohol Clin Exp Res 2003, 27:396-409.
44. Pandey S.C., Zhang H., Roy A., Xu T. Deficits in amygdaloid cAMP-responsive element-binding protein signaling play a role in genetic predisposition to anxiety and alcoholism. J Clin Invest 2005, 115:2762-2773.
45. Kudryavtseva N.N., Bakshtanovskaya I.V., Koryakina L.A. Social model of depression in mice of C57BL/6J strain. Pharmacol Biochem Behav 1991, 38:315-320.
46. Nakanishi S., Takahashi I., Kawahara K., Tsukuda E., Sano T., Yamada K., et al. Wortmannin, a microbial product inhibitor of myosin light chain kinase. J Biol Chem 1992, 267:2157-2163.
47. Ferby I.M., Waga I., Hoshino M., Kume K., Shimizu T. Wortmannin inhibits mitogen-activated protein kinase activation by platelet-activating factor through a mechanism independent of p85/p110-type phosphatidylinositol 3-kinase. J Biol Chem 1996, 271:11,684-11,688.
48. Borelli M.I., Francini F., Gagliardino J.J. Autocrine regulation of glucose metabolism in pancreatic islets. Am J Physiol Endocrinol Metab 2004, 286:E111-E115.
49. De Luca J.P., Garnache A.K., Rulfs J., Miller T.B. Wortmannin inhibits insulin-stimulated activation of protein phosphatase 1 in rat cardiomyocytes. Am J Physiol 1999, 276:H1520-H1526.
50. Zawalich W.S., Tesz G.J., Zawalich K.C. Inhibitors of phosphatidylinositol 3-kinase amplify insulin release from islets of lean but not obese mice. J Endocrinol 2002, 174:247-258.
51. Nunoi K., Yasuda K., Tanaka H., Kubota A., Okamoto Y., Adachi T., et al. Wortmannin, a PI3-kinase inhibitor: promoting effect on insulin secretion from pancreatic beta cells through a cAMP-dependent pathway. Biochem Biophys Res Commun 2000, 270:798-805.
52. Zawalich W.S., Zawalich K.C. A link between insulin resistance and hyperinsulinemia: inhibitors of phosphatidylinositol 3-kinase augment glucose-induced insulin secretion from islets of lean, but not obese, rats. Endocrinology 2000, 141:3287-3295.
53. Bradley E.A., Clark M.G., Rattigan S. Acute effects of wortmannin on insulin's hemodynamic and metabolic actions in vivo. Am J Physiol Endocrinol Metab 2007, 292:E779-E787.